Up 45% This Year What's Driving The Growth For Eli Lilly Stock?
The stock has been on a strong run for the last few years, primarily due to its pipeline potential.
You had to be in Eli Lilly before we got its results, not after, says Jim Cramer
'Mad Money' host Jim Cramer talks investing in the current market and why it can sometimes feel like a rigged game.
Eli Lilly Rises Again as Stock Upgraded Following Mounjaro Sales Surge
Jefferies analyst Akash Tewari upgraded shares of Eli Lilly to Buy from Hold.
Insurers face long road, high cost to cover obesity drugs after promising Wegovy heart health data
There is likely a long way to go before the U.S. sees increased insurance coverage of obesity drugs, but Novo Nordisk's new data is a meaningful start.
Fmr. FDA Commissioner Dr. Scott Gottlieb on diabetes drugs: Overall it's being used appropriately
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss the growing interest in new diabetes drugs, with some showing promise for weight loss and heart disease prevention, the prom...
I get stories every day from patients about how Mounjaro is benefiting their lives: Eli Lilly CEO
Eli Lilly CEO David Ricks joins 'Mad Money' host Jim Cramer to talk the recent stock pop, Eli Lilly weight-loss drug and more.
Eli Lilly Has A Big Stake In Weight Loss And Alzheimer's Drugs; But Is The Stock A Buy?
Eli Lilly surged 15% in one day on enthusiasm for weight-loss and Alzheimer's drugs. But is LLY stock a buy now?
Eli Lilly's stock jumps on promising weight-loss drug
Dr. Ezekiel Emanuel, fmr. Obama White House health policy advisor, joins 'Last Call' to talk the Eli Lilly's stock reaction to its weight-loss drug, rising obesity rates in the U.S. and more.
Eli Lilly beats on Q2 revenue and profit driven by 'a collection' of name brand drug sales: Analyst
Pharma giant Eli Lilly's (LLY) stock is soaring after reporting a second-quarter earnings beat, boasting revenue of $8.31 billion and earnings of $2.11 per share. Raising its full-year guidance, th...
Wells Fargo's Mohit Bansal sees durable growth behind Eli Lilly's blockbuster products
Mohit Bansal, Wells Fargo equity analyst, joins 'Power Lunch' to discuss Eli Lilly quarterly results as shares soar on Q2 earnings and revenue beats.
Eli Lilly (LLY) Stock Just Reached a New All-Time High
Pharmaceutical giant Eli Lilly (NYSE: LLY ) delighted investors with an impressive earnings performance, sending LLY stock to a new all-time high. In particular, the company's diabetes treatment Mo...
Weight-Loss Drug Frenzy Drives Eli Lilly And Novo Nordisk Stock To Record Highs
Shares of Eli Lilly and Novo Nordisk both soared to record highs on Tuesday, as sales increased of Eli Lilly's Mounjaro and as Novo Nordisk reports a promising clinical trial of its drug Wegovy.
Eli Lilly (LLY) Q2 Earnings Beat, Mounjaro Powers Sales Growth
Eli Lilly (LLY) beats second-quarter estimates for earnings and sales. It raises its financial guidance for 2023.
Eli Lilly Beats Estimates and Boosts Its Guidance as Diabetes Drug Sales Soar
Eli Lilly shares rose to a record after the company posted better-than-expected results and raised its guidance on soaring demand soared for its diabetes drug, Mounjaro.
Compared to Estimates, Lilly (LLY) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to...
Related Companies